FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
暂无分享,去创建一个
Liang Zhao | Hui Zhang | Richard Pazdur | Qi Liu | Reena Philip | Thomas Gwise | Rajeshwari Sridhara | Reena Philip | Amy McKee | R. Pazdur | A. Russell | Todd R. Palmby | Geoffrey Kim | R. Sridhara | Shenghui Tang | A. Ibrahim | Liang Zhao | A. Tzou | Abraham Tzou | Geoffrey Kim | G. Ison | Qi Liu | T. Gwise | Gwynn Ison | Shenghui Tang | Amna Ibrahim | Amy E McKee | Eunice Lee | Haw-Jyh Chiu | Tiffany K Ricks | Todd Palmby | Anne Marie Russell | Gaetan Ladouceur | Elimika Pfuma | Hongshan Li | Rajesh Venugopal | Haw-Jyh Chiu | Tiffany K. Ricks | E. Pfuma | Hui Zhang | E. Lee | G. Ladouceur | Hongshan Li | R. Venugopal | Geoffrey S. Kim
[1] References , 1971 .
[2] J. Thigpen,et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[4] D. Bentley,et al. Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.
[5] F. Parazzini,et al. Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients. , 1999, British journal of cancer.
[6] A. D’Andrea,et al. The Fanconi anaemia/BRCA pathway , 2003, Nature Reviews Cancer.
[7] D. Gershenson,et al. Third‐line chemotherapy in platinum‐ and paclitaxel‐resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients , 2004, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[8] J. Krischer,et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases , 2005, Cancer.
[9] B. Friedenson,et al. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers , 2007, BMC Cancer.
[10] T. Kasamatsu,et al. Usefulness of third-line chemotherapy for women with recurrent ovarian, fallopian tube, and primary peritoneal cancer who receive platinum/taxane regimens as first-line therapy , 2009, Journal of Cancer Research and Clinical Oncology.
[11] E. Friedman,et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Barry Rosen,et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. , 2011, Gynecologic oncology.
[13] Gord Glendon,et al. Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .
[14] J. George,et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Thigpen. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer , 2012 .
[16] Y. Pommier,et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.
[17] A. Fishman,et al. Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer. , 2013, European journal of obstetrics, gynecology, and reproductive biology.
[18] A. Reuss,et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] D. Matei,et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .
[20] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] A. Jimeno,et al. FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers , 2015, Clinical Cancer Research.